Format

Send to

Choose Destination
J Pept Sci. 2016 Apr;22(4):196-200. doi: 10.1002/psc.2858. Epub 2016 Feb 16.

Degradation of Akt using protein-catalyzed capture agents.

Author information

1
Division of Chemistry and Chemical Engineering, California Institute of Technology, MC 127-72, Pasadena, CA 91125.
#
Contributed equally

Abstract

Abnormal signaling of the protein kinase Akt has been shown to contribute to human diseases such as diabetes and cancer, but Akt has proven to be a challenging target for drugging. Using iterative in situ click chemistry, we recently developed multiple protein-catalyzed capture (PCC) agents that allosterically modulate Akt enzymatic activity in a protein-based assay. Here, we utilize similar PCCs to exploit endogenous protein degradation pathways. We use the modularity of the anti-Akt PCCs to prepare proteolysis targeting chimeric molecules that are shown to promote the rapid degradation of Akt in live cancer cells. These novel proteolysis targeting chimeric molecules demonstrate that the epitope targeting selectivity of PCCs can be coupled with non-traditional drugging moieties to inhibit challenging targets.

KEYWORDS:

Akt; PROTAC; click chemistry; protein-catalyzed capture agents

PMID:
26880702
PMCID:
PMC4883657
DOI:
10.1002/psc.2858
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center